Tuesday, November 19, 2013 3:42:13 PM
AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.
Recent ATRC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 12:57:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 04:44:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 04:33:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 01:56:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 01:25:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 01:25:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 01:25:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 12:24:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 08:21:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:01:48 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 09:05:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 04:31:27 PM
- AtriCure Reports First Quarter 2026 Financial Results • Business Wire • 05/05/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:00:13 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 09:11:12 PM
- AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference • Business Wire • 04/28/2026 12:00:00 PM
- AtriCure to Announce First Quarter 2026 Financial Results • Business Wire • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 03:55:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/06/2026 03:54:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 12:14:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/12/2026 08:38:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 12:52:43 PM
- AtriCure to Participate in the Citizens Life Sciences Conference • Business Wire • 02/24/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/19/2026 05:39:55 PM
